This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A two-step molecular targeting approach involving a self-assembling and disassembling (SADA) bispecific antibody platform and DOTA-radioconjugates allows tumor-specific delivery of diagnostic and therapeutic payloads. Low immunogenicity and the modular nature of SADA allow its optimization to safely and repeatedly deliver a variety of payloads to tumors expressing diverse tumor-specific antigens.
See related article by Santich et al., p. 532
Footnotes
Clin Cancer Res 2021;27:377–9
- Received October 9, 2020.
- Revision received October 18, 2020.
- Accepted October 30, 2020.
- Published first November 3, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 27, Issue 2
Volume 27, Issue 2
A New Generation of “Magic Bullets” for Molecular Targeting of Cancer
Jump to section
Advertisement